Compass Pathways Says Rolling Review Request Granted by FDA
Idag, 17:07
Idag, 17:07
11:07 AM EDT, 04/24/2026 (MT Newswires) -- Compass Pathways (CMPS) said Friday the US Food and Drug Administration has granted its rolling review request for its new drug application and selected COMP360 for the Commissioner's National Priority Voucher program for treatment-resistant depression.
Companies selected for the program are eligible for benefits including enhanced communications and a shortened 1-2 month review time, the company said.
Price: 9.17, Change: +0.02, Percent Change: +0.22
Idag, 17:07
11:07 AM EDT, 04/24/2026 (MT Newswires) -- Compass Pathways (CMPS) said Friday the US Food and Drug Administration has granted its rolling review request for its new drug application and selected COMP360 for the Commissioner's National Priority Voucher program for treatment-resistant depression.
Companies selected for the program are eligible for benefits including enhanced communications and a shortened 1-2 month review time, the company said.
Price: 9.17, Change: +0.02, Percent Change: +0.22
Rapporter
Analys
Valet 2026
Rapporter
Analys
Valet 2026
1 DAG %
Senast
OMX Stockholm 30
−0,97%
(vid stängning)
OMX Stockholm 30
1 DAG %
Senast
3 101,08